Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $7.0 million.

  • Lifecore Biomedical, Inc. \De\'s Receivables - Other rose 7151.63% to $7.0 million in Q2 2025 from the same period last year, while for May 2025 it was $7.0 million, marking a year-over-year increase of 7151.63%. This contributed to the annual value of $7.0 million for FY2025, which is 7151.63% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s Receivables - Other is $7.0 million, which was up 7151.63% from $6.1 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Receivables - Other ranged from a high of $13.9 million in Q1 2022 and a low of $2.9 million during Q4 2023
  • Moreover, its 5-year median value for Receivables - Other was $6.6 million (2025), whereas its average is $7.5 million.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Receivables - Other skyrocketed by 202000.0% in 2021 and then crashed by 6925.0% in 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Receivables - Other (Quarter) stood at $12.6 million in 2021, then plummeted by 33.33% to $8.4 million in 2022, then plummeted by 65.48% to $2.9 million in 2023, then skyrocketed by 96.48% to $5.7 million in 2024, then rose by 22.48% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q2 2025, $6.1 million for Q1 2025, and $5.7 million during Q4 2024.